Siemens Healthcare Diagnostics
and JEOL have signed a strategic partnership for the design, manufacture, and
distribution of advanced clinical chemistry platforms for the global clinical
laboratory market, which experienced an estimated 5% growth in 2010 and is
expected to climb in the future. This 10-year agreement also extends an
existing Siemens-JEOL relationship targeted at enhancing current systems within
Siemens’ clinical chemistry portfolio. Both aspects of the partnership help
ensure that mid- to high-volume laboratories can continue accessing innovative
technologies that support gains in efficiency, reliability, and accuracy.
The evolving needs of laboratories worldwide are requiring clinical
chemistry analyzers to deliver better workstation consolidation that minimizes
costs, optimizes productivity, and provides access to an expanding test menu.
For mid- to high-volume laboratories in particular, they must also be able to
fluidly manage peak workload requirements and consistently meet high
turnaround-time benchmarks. Recognizing the increased demands the current
laboratory environment is placing on these tools, Siemens and JEOL will focus
on meeting these needs by developing clinical chemistry platforms. This
partnership will also be leveraged to further streamline and enhance Siemens’
ADVIA line of clinical chemistry analyzers.
Siemens
Healthcare Diagnostics, www.siemens.com/healthcare
